Home>>Signaling Pathways>> Neuroscience>> Neurokinin Receptor>>Fezolinetant (ESN-364)

Fezolinetant (ESN-364)

Catalog No.GC30104

Fezolinetant (ESN-364) is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes.

Products are for research use only. Not for human use. We do not sell to patients.

Fezolinetant (ESN-364) Chemical Structure

Cas No.: 1629229-37-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$277.00
In stock
1mg
$101.00
In stock
5mg
$351.00
In stock
10mg
$513.00
In stock
25mg
$1,026.00
In stock
50mg
$1,638.00
In stock
100mg
$2,652.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes.

Fezolinetant (ESN364, 1 mg/kg, iv bolus) reversibly inhibits the regular, pulsatile secretion of LH in the ovarectomized ewe. ESN364 represses the pulse pattern of LH in all treated animals. ESN364 (5 mg/kg, p.o.) lowers plasma LH, but not FSH, in the castrated monkey. ESN364 (10, 25, 50 mg/kg, orally) also blocks the LH surge and decreases ovarian hormone levels throughout the menstrual cycle in monkeys[1].

[1]. Fraser GL, et al. The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle. Endocrinology. 2015 Nov;156(11):4214-25.

Reviews

Review for Fezolinetant (ESN-364)

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fezolinetant (ESN-364)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.